This year, the Osteosarcoma Institute (OSI) awarded over $1.7 million in osteosarcoma research funding to four national and international grant recipients through its 2023-2024 grant cycle. After a rigorous review of 24 submissions, the OSI’s expert review committee selected four innovative osteosarcoma research projects. These proposals demonstrated rigorous science and the potential to push osteosarcoma treatment forward.
“Some studies we fund are called high-risk studies because they may not get past the first year if the theory does not work,” says Lee Helman, MD, the OSI’s director and an expert in the field of osteosarcoma. “We need breakthroughs to move the field forward. We need to do something different than we have been doing for the last 30 years.”
The Frontline spoke with Dr. Helman to learn about each of this year’s funded cancer research projects.